HRS4R
Vull donar
Firma
ÀLVAR ROSELLÓ-SERRANO
Posició
Investigador/a Pre-doctoral – R1
Investigadors/es Pre-doctorals – R1

Projectes

Codi oficial: 2021 SGR 01463 - ONCORFIM Girona Data inici: 01/01/2022 Data fi: 30/06/2025 Investigador/a principal: ARANTXA ERASO URIÉN Organisme finançador: AGÈNCIA DE GESTIÓ UNIVERSITARIS I RECERCA

Publicacions

Barclay NL, Burkard T, Burn E, Delmestri A, Miquel Dominguez A, Golozar A, Guarner-Argente C, Avilés-Jurado FX, Man WY, Roselló Serrano À, Rosen AW, Tan EH, Tietzova I, Prieto Alhambra D, Newby D

The Impact of the COVID-19 Pandemic on Incidence and Short-Term Survival for Common Solid Tumours in the United Kingdom: A Cohort Analysis

Clinical Epidemiology, 2024, 16, 417-429 dx.doi.org/10.2147/CLEP.S463160
Barclay NL, Català M, Jödicke AM, Prieto-Alhambra D, Newby D, Delmestri A, Man WY, Serrano ÀR, Moncusí MP

Collateral effects of the COVID-19 pandemic on endocrine treatments for breast and prostate cancer in the UK: a cohort study

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16 dx.doi.org/10.1177/17588359241253115
Tan EH, Burn E, Barclay NL, Delmestri A, Man WY, Golozar A, Serrano ÀR, Duarte-Salles T, Cornford P, Prieto Alhambra D, Newby D

Incidence, Prevalence, and Survival of Prostate Cancer in the UK.

JAMA Network Open, 2024, 7 dx.doi.org/10.1001/jamanetworkopen.2024.34622
Barclay, NL, Català, M, Jödicke, AM, Prieto-Alhambra, D, Newby, D, Delmestri, A, Man, WY, Serrano, AR, Moncusí, MP

COLLATERAL EFFECTS OF THE COVID-19 PANDEMIC ON ENDOCRINE TREATMENTS FOR BREAST AND PROSTATE CANCER IN THE UK: IMPLICATIONS FOR BONE HEALTH

AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2024, 36, 452-453
Bonet M, González D, Baquedano JE, García E, Altabas M, Casas F, Feltes N, Ferrer F, Foro P, Fuentes R, Galdeano M, Gomez D, Henriquez I, Jové J, Lozano J, Maldonado X, Mases J, Membrive I, Paredes S, Roselló À, Sancho G, Mira M

Management of high-risk and post-operative non-metastatic prostate cancer in Catalonia: an expert Delphi consensus

CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25, 1017-1023 dx.doi.org/10.1007/s12094-022-03005-4
Zamora V, Garin O, Suárez JF, Jové J, Castells M, Ferrer F, Gutiérrez C, Guedea F, Boladeras A, Fumadó L, Roselló A, Pastor J, Samper P, Pont À, Ferrer M

Psychometric validation of the Spanish version of the Expanded Prostate Cancer Index Composite-26.

WORLD JOURNAL OF UROLOGY, 2023, 41, 3511-3518 dx.doi.org/10.1007/s00345-023-04691-7
Fizazi, K, Foulon, S, Carles, J, Roubaud, G, McDermott, R, Flechon, A, Tombal, B, Supiot, S, Berthold, D, Ronchin, P, Kacso, G, Gravis, G, Calabro, F, Berdah, JF, Hasbini, A, Silva, M, Thiery-Vuillemin, A, Latorzeff, I, Mourey, L, Laguerre, B, Abadie-Lacourtoisie, S, Martin, E, El Kouri, C, Escande, A, Rosello, A, Magne, N, Schlurmann, F, Priou, F, Chand-Fouche, ME, Freixa, SV, Jamaluddin, M, Rieger, I, Bossi, A

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design

LANCET, 2022, 399, 1695-1707 dx.doi.org/10.1016/S0140-6736(22)00367-1
Lopes de Castro C, Fundowicz M, Roselló A, Jové J, Deantonio L, Aguiar A, Pisani C, Villà S, Boladeras A, Konstanty E, Kruszyna-Mochalska M, Milecki P, Jurado-Bruggeman D, Lencart J, Modolell I, Muñoz-Montplet C, Aliste L, Torras MG, Puigdemont M, Carvalho L, Krengli M, Guedea F, Malicki J

Results of the IROCA international clinical audit in prostate cancer radiotherapy at six comprehensive cancer centres

SCIENTIFIC REPORTS, 2021, 11, 12323-12323 dx.doi.org/10.1038/s41598-021-91723-0
Bosch-Barrera J, Oliva E, Sais E, Vásquez CA, Roselló A, Menéndez JA

Hyperprogression after first dose of immunotherapy in a patient with radioresistant metastasis from nonsmall cell lung cancer

ANTI-CANCER DRUGS, 2019, 30, 1067-1070 dx.doi.org/10.1097/CAD.0000000000000837

Formulari de contacte

Coneix l’IDIBGI!

menu